Alexion’s Soliris Successor Among New Drugs Under EMA Review
Executive Summary
Alexion Pharmaceuticals’ successor to its blockbuster Soliris is among the new investigational drugs being reviewed for EU marketing approval.
You may also be interested in...
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
Alexion Gets Speedy Review For Soliris Successor
Switching patients from the very expensive ultra rare disorder drug to ravulizumab will be a key strategy for Alexion if the latter is approved. Recent compelling data in paroxysmal nocturnal hemoglobinuria patients suggests the long-acting C5 complement inhibitor could offer more benefit than its predecessor with more convenient dosing.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.